Roche’s Alzheimer’s drug fails to meet goal in long awaited trial
Trials show small benefit, but without statistical validityRoche's setback leaves Biogen, Eisai as leaders in the fieldOnus on Roche CEO-designate to revive development fortunesRoche shares down 3.4%, development partner Morphosys down…